Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of FT819 in Subjects With B-cell Malignancies

Next Previous
Search
Trial Profile

A Phase I Study of FT819 in Subjects With B-cell Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FT 819 (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Acronyms Landmark
  • Sponsors Fate Therapeutics

    • Most Recent Events

    • 02 Aug 2024 Status changed from recruiting to active, no longer recruiting.
    • 09 May 2024 According to a Fate Therapeutics media release, the Company has successfully completed dose escalation in its Phase 1 BCM study.
    • 22 Apr 2024 According to a Fate Therapeutics media release, the company will present data of key therapeutic mechanisms of activity for autoimmune diseases, including B cell depletion, tissue infiltration and immune reconstitution, from this study at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top